Publications

Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH

 23
Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH

Tags:

Previous Article

Human Schwann cell lipid dysregulation and plasma membrane perturbation in Charc...

Next Article

FerroTerminator1 as a potent therapeutic drug for MASH

Related Posts

Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)

Lipotoxicity-driven metabolic dysfunction-associated st...

 31

Acquiring musculoskeletal skills with curriculum- based reinforcement learning

Acquiring musculoskeletal skills with curriculum- based...

 27

Lipoprotein metabolism mediates hematopoietic stem cell responses under acute anemic conditions

Lipoprotein metabolism mediates hematopoietic stem cell...

 24